BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 26141568)

  • 1. Redoxal, an inhibitor of de novo pyrimidine biosynthesis, augments APOBEC3G antiviral activity against human immunodeficiency virus type 1.
    Pery E; Sheehy A; Miranda Nebane N; Misra V; Mankowski MK; Rasmussen L; Lucile White E; Ptak RG; Gabuzda D
    Virology; 2015 Oct; 484():276-287. PubMed ID: 26141568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.
    Pery E; Sheehy A; Nebane NM; Brazier AJ; Misra V; Rajendran KS; Buhrlage SJ; Mankowski MK; Rasmussen L; White EL; Ptak RG; Gabuzda D
    J Biol Chem; 2015 Apr; 290(16):10504-17. PubMed ID: 25724652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
    Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
    J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
    Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of benzimidazole derivatives to inhibit HIV-1 replication through protecting APOBEC3G protein.
    Pan T; He X; Chen B; Chen H; Geng G; Luo H; Zhang H; Bai C
    Eur J Med Chem; 2015 May; 95():500-13. PubMed ID: 25847768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vpr14-88-Apobec3G fusion protein is efficiently incorporated into Vif-positive HIV-1 particles and inhibits viral infection.
    Ao Z; Yu Z; Wang L; Zheng Y; Yao X
    PLoS One; 2008 Apr; 3(4):e1995. PubMed ID: 18414671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A naturally occurring Vif mutant (I107T) attenuates anti-APOBEC3G activity and HIV-1 replication.
    Peng J; Ao Z; Matthews C; Wang X; Ramdahin S; Chen X; Li J; Chen L; He J; Ball B; Fowke K; Plummer F; Embree J; Yao X
    J Mol Biol; 2013 Aug; 425(16):2840-52. PubMed ID: 23707381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages.
    Chaipan C; Smith JL; Hu WS; Pathak VK
    J Virol; 2013 Jan; 87(1):444-53. PubMed ID: 23097438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC.
    Zuo T; Liu D; Lv W; Wang X; Wang J; Lv M; Huang W; Wu J; Zhang H; Jin H; Zhang L; Kong W; Yu X
    J Virol; 2012 May; 86(10):5497-507. PubMed ID: 22379088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multifaceted counter-APOBEC3G mechanisms employed by HIV-1 Vif.
    Britan-Rosich E; Nowarski R; Kotler M
    J Mol Biol; 2011 Jul; 410(5):1065-76. PubMed ID: 21763507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small-molecule inhibition of HIV-1 Vif.
    Nathans R; Cao H; Sharova N; Ali A; Sharkey M; Stranska R; Stevenson M; Rana TM
    Nat Biotechnol; 2008 Oct; 26(10):1187-92. PubMed ID: 18806783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HDAC6/APOBEC3G complex regulates HIV-1 infectiveness by inducing Vif autophagic degradation.
    Valera MS; de Armas-Rillo L; Barroso-González J; Ziglio S; Batisse J; Dubois N; Marrero-Hernández S; Borel S; García-Expósito L; Biard-Piechaczyk M; Paillart JC; Valenzuela-Fernández A
    Retrovirology; 2015 Jun; 12():53. PubMed ID: 26105074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. APOBEC3G complexes decrease human immunodeficiency virus type 1 production.
    Martin KL; Johnson M; D'Aquila RT
    J Virol; 2011 Sep; 85(18):9314-26. PubMed ID: 21752914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells.
    Casartelli N; Guivel-Benhassine F; Bouziat R; Brandler S; Schwartz O; Moris A
    J Exp Med; 2010 Jan; 207(1):39-49. PubMed ID: 20038599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions.
    Xu H; Chertova E; Chen J; Ott DE; Roser JD; Hu WS; Pathak VK
    Virology; 2007 Apr; 360(2):247-56. PubMed ID: 17126871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 Escape from Small-Molecule Antagonism of Vif.
    Sharkey M; Sharova N; Mohammed I; Huff SE; Kummetha IR; Singh G; Rana TM; Stevenson M
    mBio; 2019 Feb; 10(1):. PubMed ID: 30808702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Various strategies for developing APOBEC3G protectors to circumvent human immunodeficiency virus type 1.
    Bao Q; Zhou J
    Eur J Med Chem; 2023 Mar; 250():115188. PubMed ID: 36773550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
    Russell RA; Pathak VK
    J Virol; 2007 Aug; 81(15):8201-10. PubMed ID: 17522216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of heat-shock protein 70 by prostaglandin A₁ inhibits HIV-1 Vif-mediated degradation of APOBEC3G.
    Sugiyama R; Abe M; Nishitsuji H; Murakami Y; Takeuchi H; Takaku H
    Antiviral Res; 2013 Sep; 99(3):307-11. PubMed ID: 23831493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The HIV-1 accessory protein Vpr induces the degradation of the anti-HIV-1 agent APOBEC3G through a VprBP-mediated proteasomal pathway.
    Zhou D; Wang Y; Tokunaga K; Huang F; Sun B; Yang R
    Virus Res; 2015 Jan; 195():25-34. PubMed ID: 25200749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.